Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Neuland Laboratories Ltd

NEULANDLAB.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: STRONG BUY

Last Close

$244.34

▲ +0.49%

Market Cap $3.13B · Vol 83.74K

Key Metrics

P/E Ratio

60.11

FWD: 56.41

Market Cap

$3.13B

Mid Cap

Div Yield

0.15%

Annual dividend

EPS Growth

+30.89%

YoY

RSI (14)

74.44

Momentum

Beta

1.29

vs Market

52W High

$247.80

1.40% below

52W Low

$120.49

99.39% above

Volume

83.74K

Avg 83.26K

P/B

8.23

Price-to-book

ROE

21.42%

Return on equity

Free Float

62.26%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Neuland Laboratories Ltd (NEULANDLAB.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NEULANDLAB.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.03%

+22.74%

+39.81%

+78.62%

YTD

+53.67%

+75.63%

+402.36%

+1,271.24%

Financials & Valuation

TTM · Annual

Total Revenue	$216.46M
Net Income	$38.95M
Revenue Growth (YoY)	+119.15%
Gross Margin	51.41%
Operating Margin	24.22%
Net Profit Margin	17.99%
ROE	21.42%
ROA · ROIC	19.14% · 19.53%

P/E Ratio	60.11
Forward P/E (FY1)	56.41
PEG Ratio	1.06
P/S	7.63
P/B	8.23
P/FCF	N/A
EPS Growth	+30.89%
Outstanding Shares	12.83M

Technical Indicators

50-Day SMA	$198.85
200-Day SMA	$167.30
RSI (14)	74.44
Beta	1.29
52-Week High	$247.80
52-Week Low	$120.49

Volume Today	83.74K
Avg Daily Volume (30D)	83.26K
Relative Volume	1.01x
Volatility (10D)	52.82
Volatility (30D)	41.67
Free Float	62.26%

Analyst Consensus

STRONG BUY

Current Price $244.34

Mean Target $255.75

52W Low$120.49 52W High$247.80

Current

Target

$120.49 $247.80

Current Analyst target

+4.67% upside potential · 5 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S8DXL9

ISININE794A01010

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.